Volume 12, Issue 3 (12-2022)                   Clin Exc 2022, 12(3): 24-34 | Back to browse issues page

XML Persian Abstract Print

Department of Public Health, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.
Abstract:   (1140 Views)
Crohn’s disease is a chronic  and common bowel disease caused gestational tract (GI) inflammation. In recent years, the prevalence of this disease has been increasing slowly  in the world and Iran .This study briefly introduces Crohn's disease with a review of related articles published during 2004-2021.
The most accepted theory of the pathophysiology of Crohn's disease is having a genetic background (CARD25/NOD2 mutations and polymorphisms of TLR), along with the abnormal response of the intestinal normal flora. Diarrhea, abdominal pain, bloating, and weight loss are the most common symptoms of the disease. To diagnose, clinical symptoms, physical examination, laboratory tests, endoscopy and colonoscopy are helpful.The aim of the treatment is to control the symptoms, reduce clinical symptoms, prevent the progression of the disease, reduce the need for surgery, nutritional support, and reduce its side effects.Moreover,anti-tumor necrosis factors  and corticosteroid medications to regulate the immune system are used. New biological agents such as anti-integrin medications have opened a better perspective for patients. To reach a good care and treatment, it is requires a team including the patient, health care workers, internal specialists, endocrinologists, infectious disease specialists, and epidemiologists to work together to meet health and treatment needs, physical and psychological support, creating health and preventive measures, approaches fast diagnosis and timely action. Due to the unknown cause of the disease and the lack of adequate treatment response to the existing medications, investigate and research more widely about Crohn's disease is needed.
Full-Text [PDF 604 kb]   (914 Downloads)    
Type of Study: Review | Subject: داخلی
Received: 2021/11/20 | Accepted: 2023/01/18 | Published: 2023/01/18

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.